96 Well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Customize your library by Cherry Picking or Procurement Services.

Not only can you personalize your library with chemicals from within Selleck’s inventory, but we can also purchase chemicals from other companies and integrate them into your custom library.

Product Description

Description & Advantages

  • A unique collection of 277 kinase inhibitors for high throughput screening (HTS) and high content screening (HCS)
  • Bioactivity and safety confirmed by preclinical research and clinical trials
  • Some inhibitors have been approved by the FDA
  • Targets kinases such as RTKs, PI3K, Aurora Kinase, CDK, and MEK
  • Most are ATP competitive
  • Structurally diverse, medicinally active, and cell permeable
  • Rich documentation with structure, IC50, and customer reviews
  • NMR and HPLC validated to ensure high purity

Product Details

Formulation: A collection of 277 kinase inhibitors supplied as pre-dissolved DMSO solutions
Container: 96 Well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Stability:
2 weeks 4°C in DMSO
3 months -20°C in DMSO
6 months -80°C in DMSO
Shipping: Blue ice
Packaging: Inert gas

Kinase Inhibitor Library Composition

Kinase Inhibitor Library Composition

Customer Reviews (5)

AS-605240 Review
Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine. AS-605240 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results AS-605240 treatment resulted in a reduction of AKT phosphorylation in T47D cells.
Axitinib and PF2341066(Crizotinib) Reviews
Click to enlarge
Rating
Source J Biomol Screen , 2011, 16, 141-154. Axitinib purchased from Selleck
Method Western blot, Multiplexing VimPro-Fluc-MDA-MB-231 spheroid viability
Cell Lines MDA-MB-231 cells
Concentrations 0-100 µM
Incubation Time 24 h
Results When Vimpro-Fluc activity is downregulated between 50% and 70%, there is significant downregulation of vimentin protein expression. When Vimpro-Fluc downregulation reaches ≥70%, then downregulation of vimentin protein expression is more pronounced. of the modulators tested-U0126, dasatinib, axitinib, and pF2341066-all downregulated Vimpro-Fluc activity by≥70%, which correlated with a significant down-reglation of vimentin protein expression. Finally, dose-response curves were generated with both U0126 (IC50 = 2.5 µM) and axitinib (IC50 = 0.25 µM), demonstrating that these small molecules modulate Vimpro-Fluc activity in a dose-dependent manner, indicating that their respective target(s) and signaling pathways play a significant role in maintaining vimentin expression and possibly mesenchymal homeostasis (Fig. B).
Axitinib and PF2341066(Crizotinib) Reviews
Click to enlarge
Rating
Source J Biomol Screen, 2011, 16, 141-154. Axitinib purchased from Selleck
Method Secondary assay
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results U0126, pF2341066, axitinib, and pKC412 caused significant inhibition of the invasive potential of Mda-Mb-231 spheroids. Conversely, dasatinib, a potent inhibitor of vimentin gene expression, did not significantly alter the invasive potential of MDA-MB-231 spheroids.
BIBW2992(Afatinib), Erlotinib(Tarceva), BMS-536924, PD-0325901 and PF02341066(Crizotinib) Reviews
Click to enlarge
Rating
Source Int J Proteomics, 2011, Article ID 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source AACR 2011Dr. Cediranib (AZD2171) purchased from Selleck
Method Cell viability assay
Cell Lines Ba/F3 cells
Concentrations 0-1000 nM
Incubation Time 72 h
Results Cediranib inhibited the survival of Ba/F3 cell lines expressing the recombinant TEL/kinase domain fusion protein for FGFR1-4 in a dose-dependent manner.

Product Citations (11)

  • (PubMed: 22250956)
  • (PubMed: 23667592)
  • (PubMed: 21613408)
  • (PubMed: 21664897)
  • (PubMed: 21536883)
  • (PubMed: 21447712)
  • (PubMed: 21285347)
  • (PubMed: 21148313)
  • (PubMed: 21106726)
  • (PubMed: 21303981)
  • (PubMed: 21403841)

See Other Libraries